Evidence map›Paper›PMID 41624404›Full record

ArticleMolecular therapy. Oncology2026

Rhabdoid tumors as a novel target for PSMA-directed CAR T cell therapy.

Aroshi Mitra, Tianyi Zhou, Jacky Wu, Tran Nguyen, Chengtai Yu, Amrita Barua, Luping Huang, Xiaoting Jiang, Rajkumar Venkatramani, Moonsoo M Jin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aroshi MitraCenter for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Tianyi ZhouCenter for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Jacky WuCenter for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Tran NguyenCenter for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Chengtai YuCenter for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Amrita BaruaCenter for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Luping HuangImmunobiology & Transplant Science Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
Xiaoting JiangImmunobiology & Transplant Science Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
Rajkumar VenkatramaniDepartment of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Moonsoo M JinDepartment of Radiology, Houston Methodist Research Institute, Houston, TX 77030, USA.
Bin HeImmunobiology & Transplant Science Center, Houston Methodist Research Institute, Houston, TX 77030, USA.
Qin FengCenter for Nuclear Receptors and Cell Signaling, Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rhabdoid tumor is an ultra-rare and highly aggressive pediatric malignancy with a poor prognosis and limited therapeutic options. To identify novel immunotherapeutic targets, transcriptomic data from the Cancer Cell Line Encyclopedia were analyzed, and we found that two rhabdoid tumor cell lines exhibit high expression of prostate-specific membrane antigen (PSMA), with levels comparable to well-established PSMA-positive prostate cancer cell lines. PSMA expression in rhabdoid tumors was subsequently validated in cell lines and in a subset of primary clinical rhabdoid tumor specimens. While PSMA-directed therapies have primarily been explored in prostate cancer, we evaluated their potential in rhabdoid tumors by employing PSMA-directed chimeric antigen receptor (CAR) T cells. These CAR T cells demonstrated potent and antigen-specific cytotoxicity against PSMA-positive rhabdoid tumor cells

Indexed as

CAR T cell therapyMT: Special Issue - Advancements in pediatric cancer therapypediatric cancerPSMArhabdoid tumortargeted immunotherapy

Identifiers

PMID41624404
PMCPMC12856549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.